Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Inclusion Criteria

• •1. Histologically confirmed CD20-positive nodal or extranodal MZBCL
• •2. MZBCL patients who relapsed or progressed:
• •* At least one and a maximum of four prior lines of chemotherapy
• •* During or after the last chemotherapy or radiotherapy or
• •* Without progression within 6 months of the last dose of rituximab-based regimen
• •3. Patients age ≥ 18 years
• •4. ECOG PS 0-2
• •5. At least one bidimensionally measurable disease
• •6. Adequate hematologic, renal, and hepatic functions
• •7. Women of child-bearing potential should use two appropriate methods of contraception during the study
• •8. Written informed consent
• •2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks
• •3. Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of \< 20mg/day for indications other than lymphomas
• •4. Evidence of CNS involvement by lymphomas
• •5. Active HBV/HCV infections, known HIV infection
• •6. Prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized non-melanoma skin cancer, or small differentiated thyroid cancer
• •7. Serious concurrent disease:
• •8. Patients who are pregnant or lactating